Cassava Sciences Inc. (SAVA)
NASDAQ (CM) 
Did Cassava Sciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SAVA
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Cassava Sciences SAVA stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
Cassava Sciences (SAVA) shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug—aimed at treating Alzheimer's disease (AD)—failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Inc. SAVA stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.
Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals
The biotech says it will discontinue a second trial but will still offer full analyses of the data.
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.
What Makes Cassava Sciences (SAVA) a New Buy Stock
Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups.
Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript
Cassava Sciences, Inc. (NASDAQ:SAVA ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Rick Barry - President & Chief Executive Officer Eric Schoen - Chief Financial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright Elemer Piros - Rodman Operator Ladies and gentlemen, welcome to Cassava Sciences Report for the Third Quarter 2024.
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences Inc. NASDAQ: SAVA is a biotech developing treatments for Alzheimer's disease. The company has a lot of controversy over its lead drug, simufilam, which attempts to go further than alleviate symptoms but actually modify the underlying biology of the disease.
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
